|
Volume 272, Number 1,
Issue of January 3, 1997
pp. 353-361
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
Synthesis and Turnover of 2-Microglobulin in
Ad12-transformed Cells Defective in Assembly and Transport of Class I
Major Histocompatibility Complex Molecules*
(Received for publication, June 19, 1996)
Sigal Vinograd
Mey-Tal
,
Chana
Schechter
and
Rachel
Ehrlich
From the Department of Cell Research and Immunology, George S. Wise
Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 64978, Israel
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgment
REFERENCES
ABSTRACT
In primary embryonal fibroblasts from transgenic
mice expressing H-2 genes and a miniature swine class I transgene
(PD1), transformation with the highly oncogenic Ad12 results in a
reduction in peptide transporter and proteasome-associated (LMP2 and
LMP7) gene expression, and suppression in transport and cell surface expression of all class I antigens. The selective suppression in
transport of H-2 (but not of PD1) molecules in cells reconstituted for
the expression of peptide transporter and LMP genes implied that an
additional factor(s) is involved in the assembly of class I complexes.
Here we show that the 2m, H-2Db, and
H-2Kb genes are transcribed and translated in
Ad12-transformed cells. However, unlike normal and E1Ad5-transformed
cells, in which 2m is either secreted unbound or bound
to class I heavy chains, in Ad12-transformed cells significant amounts
of 2m are retained in the cell bound to the membrane,
but free of class I heavy chains. This abnormal turnover of
2m in the Ad12-transformed cells suggests the existence
of a novel 2m-binding molecule(s) that sequesters 2m, and this process may provide a mechanism by which
transformation with Ad12 may subvert class I complex formation.
INTRODUCTION
MHC1 class I molecules are
polymorphic, integral membrane proteins that bind a diverse group of
peptides derived from endogenous antigens and display these peptides
for recognition by cytotoxic T-lymphocytes (1). This mechanism enables
the immune system to control infectious diseases and the growth of
tumor cells (2, 3). Indeed, cells infected by a variety of viruses that
interfere with cell surface expression of class I antigens, as well as
tumors of various origins that demonstrate suppressed levels of class I
antigens, can escape immune surveillance (4).
The biochemistry and cell biology of antigen processing and
presentation by class I MHC molecules has been analyzed in detail in
recent years (5, 6). It is well established that the efficient
transport of class I molecules to the cell surface depends on the
assembly of the heavy chain/ 2m dimer with peptides that are usually 8-9 amino acids long. Such peptides, generated by cleavage
of proteins in the cytosol, are actively transported by a heterodimeric
complex, known as transporter associated with antigen presentation
(TAP), into the endoplasmic reticulum (ER), where assembly with class I
molecules takes place. The trimeric complex is then transported through
the Golgi apparatus to the cell surface. Mutant cell lines (5, 6, 7, 8),
"knockout" mice (9, 10), and tumor cells (4, 11, 12), which do not
express TAP genes, are generally devoid of cell surface MHC class I
molecules. Cell lines and knockout mice lacking 2m
expression also fail to display normal cell surface class I MHC
molecules (13, 14, 15). The crucial role of 2m is evident
from data demonstrating that it stabilizes cell surface expression of
class I heavy chains, facilitates the binding of purified class I
molecules to antigenic peptides both on cells and plastic surfaces, and generates additional high affinity peptide-binding sites in
preparations of soluble purified class I molecules (16, 17, 18, 19, 20). These
data, as well as the finding that 2m determines the fate
of class I heavy chains (21), suggest that 2m may play a
predominant role in maintaining the class I heavy chain in a
non-denatured conformation suitable for terminal folding upon binding
of peptide. Such a model predicts a role for extracellular 2m in providing a microenvironment that supports the
existence of cell surface 2m/heavy chain dimers capable
of binding peptides. Indeed, both constitutive and peptide-induced
class I surface expression can be augmented markedly, in some cases, by
the presence of exogenous 2m (21, 22). The existence of
a substantial pool of inactive heavy chains on the cell surface, which
are able to bind added 2m at 37 °C, has been
demonstrated by Rock et al. (23), implying a physiological
role for exogenous 2m in maintaining cell surface class
I heavy chains in a state suitable for subsequent binding of exogenous
peptides.
Increased levels of 2m can be detected both in the
peripheral circulation and locally, in many abnormal in vivo
conditions (24, 25, 26, 27, 28). Additionally, lymphoid and hepatoma cells have
been shown to produce and secrete 2m when stimulated with various cytokines (29, 30). If these augmented levels facilitate
the accumulation of class I-bound peptides, then the regulation of
2m secretion may have functional consequences. Supportive of such a role are data demonstrating the strong in vivo priming of cytotoxic T-lymphocytes to class I-binding
peptides if the latter are combined with 2m when
injected into mice (31).
We have shown previously that, in primary embryonal fibroblasts from
transgenic mice expressing both endogenous H-2 genes and a miniature
swine class I transgene (PD1), transformation with the highly oncogenic
Ad12 results in inhibition of the transport of newly synthesized class
I molecules via the Golgi apparatus, a significant reduction in peptide
transporter (TAP1 and TAP2) and in proteasome-associated (LMP2 and
LMP7) gene expression, and in suppression of cell surface expression of
all class I antigens (12, 32, 33, 34). Expression of these class I genes is either normal or up-regulated in cells transformed by the non-oncogenic virus-Ad5. Re-expression of TAP and LMP in an Ad12-transformed cell
line completely reconstituted the cell surface expression and transport
of PD1 and induced the transport of 20% of the H-2Db
molecules, but did not affect the transport or expression of H-2Kb molecules (34). These data, as well as the fact that
in Ad12-transformed cells, H-2 molecules were not recognized by
conformation-independent antibodies (33, 34), raised the possibility
that either the synthesis of 2m in these cells is
defective and the class I heavy chains compete for a limited amount of
2m molecules (PD1 being more competitive), or that
Ad12-transformed cells are deficient in a factor(s) that facilitate the
assembly of 2m with a particular set of class I heavy
chains (H-2). We now present data substantiating that
2m, as well as H-2Db and H-2Kb,
are transcribed and translated in Ad12-transformed cells. However, the
results show an abnormal turnover of 2m molecules and
suggest the existence of a novel 2m-binding molecule(s)
that acts to retain 2m in the transformed cells.
EXPERIMENTAL PROCEDURES
Cell Cultures
The Ad12-transformed (VAD12.79, VAD12.42,
VAD12.20, VAD12.25, VAD12.36, VAD12.54, and VAD12.43),
E1Ad5-transformed (A5O1 and A5O5), and TAP-transfected cell lines and
the normal cell line M1 have been described previously (32, 33, 34). Cells
were maintained in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10% fetal calf serum, penicillin,
streptomycin, gentamycin, and amphotericin B at the recommended
concentrations (35). Media and supplements were purchased from
Biological Industries (Bet Ha'emek, Israel).
Cell lines were treated with 600 units/ml / interferons (Lee
Biomolecular Research Inc., San Diego, CA) for 16 h, or 100 units/ml -interferon (Boehringer, Mannheim, Germany) for 48 h before harvesting.
Stable Transfection
TAP2-transfected Ad12-transformed
cells (VAD12.79 Cl1.1, Ref. 34) were transfected by the calcium
phosphate-DNA coprecipitation method (34). The transfection mixture
contained 10 µg of plasmid DNA (the 2m gene expressed
from an actin promoter in PBr was constructed in Dr. D. Margulies'
laboratory (NIAID, NIH, Bethesda, MD)), 1 µg of plasmid DNA
containing the hygromycin gene, and 5 µg of carrier DNA (sheared
salmon sperm DNA, Sigma). Twenty-four hours after
transfection, the cells were washed with PBS, fresh media was added and
after an additional 24 h the medium was supplemented with 110 units/ml hygromycin B (Calbiochem). Following selection of
hygromycin-resistant cells, individual cell colonies were isolated and
expanded in culture.
Antibodies
The following antibodies were used for
immunoprecipitation: 20.8.4S (recognizes the
1/ 2 epitope on H-2Kb; Ref.
36); B22.249 (recognizes an 1 epitope on
H-2Db; Ref. 36); PT85A (recognizes a public determinant on
swine lymphocyte antigens (SLA); Ref. 37). Rabbit antibodies directed against 2m were a kind gift from Dr. J. E. Coligan
(NIAID, NIH, Bethesda, MD).
Metabolic Labeling and Immunoprecipitation
Cells were grown
to 80% confluence and starved for 15 min in methionine-free medium.
They were then labeled in methionine-free medium containing 250 mCi/ml
[35S]methionine (Amersham International, Little Chalfort,
United Kingdom (UK)) for 15 min unless otherwise indicated, washed with PBS, and chased for the indicated intervals. Cells that were labeled for 15 h were incubated in methionine-free medium containing 16% Dulbecco's modified Eagle's medium supplemented with 10% fetal calf
serum and 100 mCi/ml [35S]methionine. The cells were
lysed with buffer containing 0.5% Triton X-100, 50 mM Tris
(pH 7.5), and 150 mM NaCl. The immunoprecipitates were
washed with buffer containing 0.1% Triton X-100, 50 mM
Tris (pH 7.5), and 150 mM NaCl. For Endo H treatment,
immunoprecipitates were eluted by adding 25 µl containing 50 mM Tris (pH 8), 1% SDS, and boiled for 5 min. The samples
were centrifuged and the supernatant was added to 25 µl of 50 mM citrate buffer (pH 5.5) containing 500 units of Endo H
(New England Biolabs). The samples were incubated at 37 °C for
18 h, followed by the addition of sample buffer. All the buffers
contained the following protease inhibitors; 1 mM
phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin (Sigma). The immunoprecipitates were
fractionated on 10 or 15% SDS-polyacrylamide gels, and X-Omat AR x-ray
films (Eastman Kodak Co.) were exposed to the dried gels.
Preparation of Membranes
Membranes were prepared as
described (38). Briefly, cell lysates were separated into two
fractions: one containing cell membranes and the other containing
soluble proteins. Cell pellets (5 × 107/ml) were
resuspended in ice-cold Dounce buffer (10 mM Tris (pH 7.6),
0.5 mM MgCl) with protein inhibitors and incubated on ice for 30 min. The cells were lysed with a Dounce homogenizer, and the
tonicity of the solution was restored by adding NaCl to a final
concentration of 0.15 M. The suspension was spun at
500 × g to remove the nuclei, and the supernatant was
further centrifuged for 45 min at 100,000 × g at
4 °C. The supernatant, which contained soluble proteins, was
transferred to a separate tube, and the pellet was resuspended in lysis
buffer.
Probes and Plasmids
The following probes have been
described previously (32, 33, 34); the actin probe was a
PstI-PstI fragment from chicken actin
cDNA, the PD1-specific probe was a SacI-BamHI
genomic fragment containing exons 2-7 of the PD1 gene, the H-2 probe
was an EcoRI-HindIII fragment derived from
pH-2d33 (H-2Kd), the 2m probe
was a PstI-PstI fragment from 2m
cDNA, and the histone probe was a BamHI genomic
fragment. Plasmids containing H-2Kb cDNA and
H-2Db genomic (pMo/Db) fragments (40) were used
as templates for PCR reactions and were a kind gift from Dr. L. Eisenbach (The Weizmann Institute of Science, Rehovot, Israel) and from
Dr. D. Pardoll (Johns Hopkins University, Baltimore, MD),
respectively.
Hybridizations
The hybridization solution contained 4 × SSC, 50% formamide, 0.2% SDS, 0.1% polyvinylpyrrolidone, and 100 µg/ml sheared salmon sperm DNA. Hybridizations were carried out at
42 °C, followed by washes with 2 × SSC, 0.1% SDS at room
temperature, and 0.2 × SSC at temperatures ranging between 55 and
65 °C. After stripping with a boiling solution of 0.1% SDS, the
blots were used for additional hybridizations.
RNA Analysis
Cytoplasmic RNA was prepared using a
modification of the White and Bancroft method (41), as described
previously (34). RNA was denatured and fractionated on a 1.2%
formaldehyde/formamide agarose gel, blotted onto a Hybond-N membrane
(Amersham International, Little Chalfort, UK) and hybridized with the
appropriate probe, which had been labeled with
[ -32P]dCTP (Rotem Industries, Dimona, Israel), using a
Random Priming labeling kit (U. S. Biochemical Corp.).
Polysome Fractionation
Polysomes were fractionated as
described previously (42). Cells were grown to 80% confluence and
harvested by trypsinization (0.25 M trypsin EDTA;
Biological Industries, Israel). A quantity of 6 × 107
cells was lysed per fractionation. The cells were washed with PBS, and
cell pellets were kept at 70 °C until used. Trypsin, PBS, and
media contained 100 µg/ml cycloheximide (Sigma).
Cells were thawed on ice and suspended in 450 µl of polysomal buffer containing 10 mM NaCl, 10 mM Tris (pH 7.4), 1.5 mM MgCl2, and 50 µl of ribonucleoside vanadyl
complexes (200 mM) (New England Biolabs). Cells were lysed
following the addition of 60 µl of polysomal buffer containing 10%
Triton X-100 and 10% deoxycholate by brief mixing before and after 3 min of incubation on ice. Nuclei were pelleted by centrifugation for 3 min at 4 °C, and the postnuclear supernatant was diluted with an
equal volume of 25 mM Tris (pH 7.5), 10 mM
MgCl2, 25 mM NaCl, 0.14 M sucrose,
500 µg/ml heparin, 0.05% Triton X-100. The suspension was layered
over 35 ml of 15-45% (w/w) sucrose gradient with a 2-ml cushion of
45% sucrose. The sucrose solution contained 25 mM Tris (pH
7.5), 25 ml of NaCl, 2 mM MgCl2. A volume of 36 µl of heparin (from a stock solution of 200 µg/ml) was added to
each gradient. The gradients were centrifuged at 26,000 rpm for 4 h at 4 °C in a Beckman SW27 rotor. After centrifugation, 38 fractions of 1 ml each were collected into tubes containing 10 µl of
10% SDS. The A260 was monitored, the polysome profile was determined,
and each 2-3 tubes were pooled to give a total of 8-10 tubes. RNA was
extracted from polysomal and subpolysomal fractions as described
before. Only gradients with identical polysomal profiles were
compared.
RT-PCR
Reverse transcription of RNA was carried out for
1 h at 42 °C, in 20 µl of PCR buffer II (Perkin Elmer)
containing 1 µg of total cellular RNA, 2.5 µM
oligo(dT)18 primer (New England Biolabs), 1 mM
nucleotide mixture, 5 mM MgCl2, 35 units of
ribonuclease inhibitor (MBI Fermentas, Vilnius, Lithuania), and 7 units
of avian myeloblastosis virus reverse trascriptase (Promega, Madison, WI). The cDNA was stored at 20 °C until used.
PCR was carried out with 1 µl of the cDNA, and 50 pmol of the
following primers (40): a 5 consensus primer for H-Db and
H-2Kb (5 -CGC GAC GCT GCT GCG CAC AG-3 ), and 3 primers
specific for H-2Db (5 -TAC AAT CTC GGA GAG ACA TT-3 ) or
H-2Kb (5 -TAC AAT CTG GGA GAG ACA GA-3 ), 40 µM nucleotide mixture, and 0.375 units of Taq
DNA polymerase (Promega). Each PCR cycle included 1 min of denaturation
at 94 °C, 1 min of annealing at 65 °C, and 1 min of
extension/synthesis at 72 °C. After the appropriate number of PCR
cycles (MiniCycler, MJ Research Inc., Watertown, MA), 10 µl or less
of the reaction mix were fractionated on a 1% agarose gel. The gel was
soaked twice for 20 min in 1.5 M NaCl, 0.5 M
NaOH at room temperature and blotted onto a Hybond-N membrane (Amersham
International, Little Chalfort, UK) with transfer buffer containing 1.5 M NaCl, 0.25 M NaOH. The membrane was baked for 10 min at 80 °C, and the DNA was cross-linked to the membrane by
exposure to UV.
Since both genes yield an RT-PCR product that is identical in size, two
positive and two negative controls were included in each set of
reactions. A plasmid containing a genomic fragment from
H-2Db was amplified with H-2Db primers and with
H-2Kb primers, and a plasmid containing H-2Kb
cDNA was amplified with H-2Kb primers and with
H-2Db primers. Since the yield of the PCR product is
proportional to the starting amount of the template, only under
conditions in which PCR amplification proceeds exponentially at a
constant efficiency (43, 44) is the PCR reaction quantitative. A
titration curve for amplified cDNA from each cell line and for each
gene was plotted to ensure that the number of amplification cycles was
below the plateau level. Detailed analysis of the results is presented
under "Results."
Quantitation of Radioactive Signals
Dried radioactive gels
or blots were exposed to a phosphoimager screen and analyzed with a
phosphoimager (Fuji BAS1000, Tokyo, Japan). The data are presented as
phosphostimulated luminescence (PSL) units. In some cases, following
scanning densitometric analysis of the x-ray films was performed.
RESULTS
Steady State Level of Class I and 2m mRNA in
Ad12-transformed Cells
Due to post-transcriptional interference
with class I assembly and transport (32, 33), most of the
Ad12-transformed cell lines express very low levels of cell surface
class I antigens despite having near normal levels of class I mRNA.
Fig. 1 (A and B) substantiates
previous data from our laboratory (12, 32), demonstrating that nearly
all the Ad12-transformed cell lines express normal or elevated levels
of the miniature swine class I transgene (PD1) mRNA, and a normal
level or less than a 2-fold reduction in H-2 mRNA, as compared with
that in the normal cell lines as exemplified by M1. The level of class
I mRNA in E1Ad5-transformed cells is either normal or enhanced.
Full restoration of cell surface expression level and transport of PD1
was achieved by re-expression of peptide transporter molecules in the
Ad12-transformed cell line VAD12.79 (12) but the expression level of
H-2Db was only partially restored, and the expression level
of H-2Kb remained very low in these TAP-reconstituted and
in TAP+LMP-reconstituted cells (12, 34). In order to examine whether
the selective suppression of H-2Kb expression was mediated
by H-2Kb-specific gene regulatory elements, the mRNA
levels of the individual H-2 genes were analyzed in the transformed
cells. Since efficient detection and quantitation of H-2 mRNA by
Northern blot analysis requires a probe that does not distinguish H-2K
from H-2D mRNA, we utilized a quantitative RT-PCR assay in order to
determine the relative amounts of mRNA encoded by each of these
genes. A total of 5-30 PCR cycles were performed for each of the
cDNAs that were reverse-transcribed from total RNA. The PCR
products were fractionated on agarose gels, blotted, hybridized to an
H-2 probe, and the radioactive signal was quantitated, following
various exposure periods. Fig. 2A shows the
results of the analyses of H-2 cDNA in one of the transformed cell
lines, using specific primers for H-2Kb and
H-2Db. The primers were complementary to the same region in
the two genes, thus minimizing possible differences that could result from DNA positioning or conformation. Since both sets of primers gave a
band of the same size, the specificity of the PCR reaction was proved
by the generation of the expected bands, using H-2Kb and
H-2Db plasmid DNA templates (Fig. 2B). Analysis
of the data showed a linear response curve when the number of PCR
cycles ranged between 10 and 25. Similar response curves were obtained
for E1Ad5-transformed (A5O1 and A5O5), Ad12-transformed (VAD12.79 and
VAD12.42), and the normal cell line M1. Using the linear part of the
curves, we compared the mRNA levels for each of the genes in the
different cell lines. A representative display of the results is shown
in Fig. 2B. The ratios in the levels between
H-2Kb and H-2Db were determined, and the values
are presented in Table I. These analyses showed that in
Ad12-transformed, as well as in the normal and E1Ad5-transformed cell
lines the ratio between H-2Kb and H-2Db
transcripts is about 1, implying that the level of H-2D and H-2K mRNA is about the same. Thus, in Ad12-transformed cells
H-2Kb is not selectively suppressed at the transcriptional
level.
Fig. 1.
Steady state level of class I heavy chains
and 2m in normal and Ad-transformed cell lines.
Electrophoresis on a formaldehyde/formamide agarose gel was carried out
with 20 µg of total RNA from the "normal" cell line (M1),
Ad12-transformed cell lines (VAD12.79, VAD12.42, VAD12.36, VAD12.25, VAD12.20, VAD12.54, and
VAD12.43), and Ad5E1-transformed cell lines (A5O1 and A5O5). RNA was
transferred to a nylon membrane and hybridized with probes specific for
PD1, H-2, 2m, and actin (A). The blot was
stripped between hybridizations, as indicated under "Experimental
Procedures." The results of the normalized densitometric analyses are
summarized in B and C. D. U.,
densitometric units; H. C., heavy chain.
[View Larger Version of this Image (30K GIF file)]
Fig. 2.
Comparison of steady state level of
H-2Kb and H-2Db mRNA as determined by
RT-PCR in normal and Ad-transformed cell lines. RT-PCR was carried
out using primers specific for H-2Kb and H-2Db.
PCR products were fractionated on agarose gels, blotted onto nylon
membranes, and hybridized with an H-2 probe. Each blot was exposed for
various time intervals, assuring that of all test points were at the
linear detection range of the phosphoimager. A response curve for
amplified cDNA from each cell line and for each gene (radioactive
signals are presented as log PSL), was plotted as a function of the
number of PCR cycles. Representative response curves are shown in
A. A representative gel, which includes samples from a
normal cell line (M1), E1Ad5-transformed cell line (A5O1 and A5O5) and
Ad12-transformed cell lines (VAD12.79 and VAD12.42), is shown in
B. The blot was exposed for various intervals, and the
results of the best exposure times are displayed. Specificity controls
using plasmid DNAs as templates are shown in the first four
lanes. The ratio between H-2Db and H-2Kb
signals in three individual experiments is summarized in Table I.
Db-g, a plasmid containing a genomic fragment of
H-2Db. Kb-c, a plasmid containing a
cDNA fragment of H-2Kb. RT-PCR prod., RT-PCR
products.
[View Larger Version of this Image (35K GIF file)]
Table I.
Relative expression of H-2Db and H-2Kb mRNA in
normal and Ad-transformed cells
M1, normal cell line; A5O1 and A5O5, E1Ad5-transformed cell lines;
VAD12.79 and VAD12.42, Ad12-transformed cell lines. PSL, phosphostimulated luminescence units.
| Exp. |
Cell line
|
| M1 |
A5O5 |
A5O1 |
VAD12.79 |
VAD12.42
|
|
|
H-2Db/H-2Kb
(PSL) |
| 1 |
1.2 |
1.1 |
0.7 |
0.8 |
2.9
|
| 2 |
0.6 |
0.7 |
|
1.7 |
1.4
|
| 3 |
1.0 |
|
|
1.1 |
|
Since a limiting amount of 2m could be a factor of major
importance in class I assembly and transport, we next determined the
levels of 2m mRNA in the transformed cells. Fig. 1
(A and C) shows that the steady state levels of
2m mRNA varied among the Ad12-transformed cell
lines. In VAD12.79 (the cell line that was transfected with TAP and LMP
genes and yet demonstrated inefficient transport of H-2 molecules), the
2m mRNA level was 2.5-fold lower than that in the
normal cell line M1 and 4-fold lower than that in the E1Ad5-transformed
cell lines. The reduced levels of 2m mRNA in
Ad12-transformed cells might limit 2m synthesis to a level whereby competition for this molecule by different class I heavy
chains results in inefficient assembly and transport of particular
class I complexes.
Translation of Class I Heavy Chains and 2m mRNA
in Ad12-transformed Cells
As we were not able to
immunoprecipitate significant amounts of H-2 molecules, even with
antibodies directed against the 3 domain or the
cytoplasmic tail of class I antigens (33, 34), the possibility that the
class I heavy chains and 2m transcripts were poorly
translated was considered. Polysome-associated RNA from normal and
Ad12-transformed cells was fractionated and hybridized with several
probes. The control probes were chosen to represent mRNAs of
1.5-kilobase mRNAs (class I heavy chain mRNA was compared with
actin mRNA), and of 0.5-kilobase mRNAs ( 2m
mRNA was compared with histone mRNA). Fig. 3
shows a representative experiment in which hybridization signals
obtained with polysomal RNA from VAD12.79 and M1 cell lines were
compared. The distribution of PD1, H-2, actin, and histone mRNAs
was identical in the two cell lines. The maximal level of class I and
actin mRNA was in fractions 2-4, and that of histone was in
fractions 5 and 6. These results are in agreement with the mRNA
sizes of these genes. The distribution of 2m mRNA
showed a slight shift toward the lighter polysome fraction in VAD12.79
(fractions 3-5 in VAD12.79, compared with fractions 2-4 in M1). While
these results were consistent in the VAD12.79 cell line, we did not
detect a similar shift in other Ad12-transformed cell lines (data not
shown). Therefore we conclude that both class I heavy chains and
2m mRNA are efficiently translated in
Ad12-transformed cell lines.
Fig. 3.
Translation efficiency of class I heavy
chains and 2m in normal and a Ad12-transformed cell
lines. Polysome-associated mRNA was isolated from a normal
cell line (M1) and an Ad12-transformed cell line (VAD12.79) and
fractionated on a formamide/formaldehyde gel. The gel was blotted and
hybridized with PD1-, H-2-, 2m-, actin-, and
histone-derived probes. L, light; H, heavy.
[View Larger Version of this Image (66K GIF file)]
Overexpression of 2m in TAP-reconstituted VAD12.79
Cells Enhances Assembly and Transport of PD1 but Does Not Affect
Assembly of H-2 Molecules
Since the intracellular concentration
of 2m might affect the efficiency of assembly of class I
complexes, we attempted to induce assembly and transport by
overexpression of 2m molecules. TAP-reconstituted
VAD12.79 cells were transfected with a vector expressing mouse
2m from an actin promoter. Several individual clones
that expressed levels of 2m identical to the normal cell line were grown, and the transport of PD1 and H-2 molecules
was analyzed by immunoprecipitation with antibodies directed against PD1 or against the H-2 heavy chains, respectively. Fig.
4 (A and B) shows two
representative pulse-chase experiments performed with two of the
transfected clones (clones 2 and 9). The transport rate of PD1 was
enhanced in both clones, as evidenced by the rate of acquisition of
Endo H resistance especially following the 60-min chase period. This
augmentation was not seen with H-2 molecules analyzed in parallel (data
not shown). These results were supported by data obtained with
TAP-reconstituted Ad12-transformed-cells infected with recombinant
vaccinia viruses expressing 2m, and with cell extracts
to which excess purified human 2m was added (data not
shown). In all three cases, an excess of 2m resulted in
augmented assembly and transport of PD1/ 2m, but did not
affect the assembly of H-2/ 2m. Thus, even in VAD12.79,
in which the 2m levels are comparable or exceed levels
in normal cells, it somehow was not accessible for assembly of H-2
class I complexes.
Fig. 4.
Transport of PD1 in
2m-transfected TAP-reconstituted VAD12.79 (12.79/TAP2)
cells. Transport of PD1 was analyzed in the normal cell line (M1),
a mixture of hygromycin-transfected clones (12.79/TAP2 C/Mix), and
2m-transfected clones (2 in A and 9 in
B), following immunoprecipitation and Endo H treatment. m, mature; imm, immature.
[View Larger Version of this Image (71K GIF file)]
Turnover of 2m in Normal and Ad12-transformed
Cells
Since increased amounts of newly synthesized
2m in the Ad12-transformed cell line did not affect the
assembly and transport of H-2 molecules, we next focused on the fate of
the 2m molecules in these cells. The level and half-life
of the assembled and the total 2m was assayed in
pulse-chase experiments with the relevant antibodies. The level of PD1
in M1 cells is 3-4-fold higher than that of H-2Kb or
H-2Db (12), and its maturation rate and half-life resembles
that of H-2Kb (33). Consequently, the turnover rate of
PD1-associated 2m is representation of the mean turnover
rate of class I-bound 2m in the cells. As can be seen in
Fig. 5 (A and B), the half-life of
PD1-assembled 2m in the normal cell line was greater
then 7 h, the half-life of total 2m molecules in
the normal and in E1Ad5-transformed cell lines was less then 100 min,
but in VAD12.79 there was minimal turnover of the 2m
during this time period. Identical results to that observed in VAD12.79
were obtained with two additional Ad12-transformed cell lines (VAD12.42
and VAD12.36; data not shown). Since the ratio of the heavy chain to
the light chain did not change during the chase periods, we feel that
the rapid turnover rate of free 2m in the normal and in
E1Ad5-transformed cell lines represents the true estimation of
2m half-life and does not result from an exchange
between labeled and non-labeled 2m molecules. Thus, our
data clearly demonstrate that both assembly of class
I/ 2m (Refs. 12 and 33; see Fig. 7, B1) and
secretion or degradation of free 2m were both abrogated
in Ad12-transformed cells.
Fig. 5.
Half-life of 2m in normal and
Ad-transformed cell lines. A representative pulse-chase experiment
demonstrating the turnover of 2m in normal (M1),
E1Ad5-transformed (A5O5), Ad12-transformed (VAD12.79), TAP1+2- and
TAP2-VAD12.79 cells is shown in A. B and C summarize the results of three pulse-chase experiments;
cell lysates were immunoprecipitated either with antibodies directed against 2m (total 2m, B and
C), or with antibodies directed against PD1 (PD1-assembled
2m, B). The mean ± S.D. of the
quantitated signals obtained for 2m was calculated as
the percent of the signal observed immediately after the 15-min pulse
(% of time zero), and is presented as a function of the chase period.
Total 2m, 2m
precipitated with antibodies directed against 2m.
PD1-assembled 2m, PD1-associated
2m in M1 cells precipitated with antibodies directed
against PD1.
[View Larger Version of this Image (27K GIF file)]
Fig. 7.
Analysis of soluble and membrane cell
fractions for the presence of 2m. Cell lysates were
prepared following hypotonic shock by Dounce homogenization
(A, B1, B2, lanes 1-4), or
by 0.1% Triton X-100 solubilization (B2, lanes
5). The lysates were separated into soluble and membrane fractions
as described under "Experimental Procedures." Following
solubilization of the membranes with 0.1% Triton X-100, both fractions
were immunoprecipitated with antibodies against 2m
(A, B2), or with antibodies against PD1
(B1). In Experiment 2 (B2), the
immunoprecipitates were fractionated under reduced or non-reduced
conditions, as specified in the figure. Nonspecific bands that
immunoprecipitated with anti-PD1 antibodies were observed mainly in the
soluble fractions and are marked with an asterisk (B1). The signals were quantitated and are presented as
PSL × 10. The specific values of the signals per microgram of
protein in the lysates were calculated and are presented in Table II. ME, 2-mercaptoethanol; Fr., fraction.
[View Larger Version of this Image (29K GIF file)]
In order to determine whether poor assembly and the factors retarding
2m turnover are related, we determined the half-life of
total 2m in TAP-reconstituted VAD12.79 cells, which can
assemble and transport PD1 molecules (12, 34). Fig. 5 (A and
C) shows that in these cells, the half-life of total
2m was comparable with that of PD1-assembled
2m, and significantly longer than that of total
2m in the normal cell line. Pretreatment of
Ad12-transformed cells with interferons, which reconstitutes almost
completely the assembly and transport of both the PD1 and H-2 molecules
(34), enhanced the turnover of 2m molecules but did not
fully restore their normal turnover rate (Fig. 6,
A and B). These results imply that in
Ad12-transformed cells there is a mechanism that acts to retain
2m in the cells and that this retention is only
partially alleviated by reconstituting the assembly of class I
complexes.
Fig. 6.
Half-life of 2m in Ad-12
transformed cell lines following treatment with interferons. A
representative pulse-chase experiment demonstrating the turnover of
total 2m in normal (M1), VAD12.79, and VAD12.79 cells
pretreated with / or -interferons is shown in A.
Panel B summarizes the results of three experiments. The
mean ± S.D. of the quantitated signals obtained for
2m was calculated as the percent of the signal observed
immediately after the 15-min pulse (% of time zero), and is presented
as a function of the chase period. Total
2m, 2m precipitated with antibodies directed against 2m.
[View Larger Version of this Image (42K GIF file)]
2m Molecules Are Associated with the Membrane
Fraction of Ad12-transformed Cells
In order to localize the
compartment where 2m is retained in Ad12-transformed
cells, we separated cell lysates into two fractions: one enriched for
soluble proteins, and the other for cell membranes. The latter fraction
was solubilized by detergent treatment, and both fractions were
immunoprecipitated with antibodies directed against 2m.
The results of two experiments are depicted in Fig. 7.
In the first (A), the cells were pulsed for 30 min in order to be able to detect molecules with short and long half-lives. In the
second (B), the cells were labeled for 15 h to enrich
for molecules that have a long half-life. In order to directly
determine which fraction was enriched with heavy chain-associated
2m molecules, we immunoprecipitated both total
(B2) and PD1-assembled 2m (B1). The immunoprecipitates were reduced or left untreated before
fractionation by polyacrylamide gel electrophoresis. The data were
quantitated and are summarized in Table II. The results
of both experiments show that the membrane fraction of the two cell
lines was enriched for 2m. Whereas in M1,
2m molecules are associated with class I heavy chains
and, therefore, were expected to reside in the membrane fraction, the
2m-enriched membrane fraction of VAD12.79 implies that
in these cells the 2m molecules are associated with another membrane component. Experiment 2 shows that PD1 resides within
the membrane fraction of M1 (B1, compare lanes 1 and 3), but, as expected, was absent from extracts of
VAD12.79 (B1, lanes 2 and 4). These
results confirmed previous data that there was no assembly of heavy
chain/ 2m in VAD12.79 cells and assured us that there was
no contamination of the soluble fraction proteins with membrane-bound
proteins. The signal obtained for the PD1-associated 2m
in M1 was comparable with the signal obtained for total
2m in the membrane fraction of the same cells
(B1, lane 3 compared with B2,
lane 3). This result indicates that most of the
2m residing in the membrane fraction of M1 cells is
bound to class I heavy chains. Unlike M1 in which all membrane-bound
2m can be accounted for by class I heavy chain
associations, in VAD12.79 some other membrane component must be playing
this role. Moreover, the association of this membrane component with
2m is more stable than the 2m-association with class I heavy chains, as evidenced by the fact that after 15 h of labeling the amount of both soluble (B2, lanes
1 and 2) and membrane 2m (B2,
lanes 3 and 4), in VAD12.79 cells was 3-fold higher than in the M1 cells, whereas after a short pulse these signals
in the membrane fraction were almost identical in both cell lines
(A, lanes 3 and 4). The binding
between this yet to be identified membrane component and
2m is not via covalent disulfide bonds, since the same
results were obtained whether or not the immunoprecipitates were
reduced before fractionation (Fig. 7).
The fact that VAD12.79 cells appear to posses a unique membrane
2m-binding component was further substantiated by the
finding that in the soluble fraction of the M1 cells, partial
degradation of 2m molecules was evident (B2,
lanes 1), while no such degradation was detected in the
soluble fraction of VAD12.79 cells (B2, lanes 2),
despite the fact that the 2m signal in these cells was
3.5-fold stronger. Degradation products of 2m molecules
were also detected in immunoprecipitates of total cell extracts from M1
cells, but not from VAD12.79 cells (B2, lanes 5 and 6, respectively).
DISCUSSION
The selective suppression in transport and cell surface expression
of H-2 molecules in Ad12-transformed cells that were reconstituted for
the expression of peptide transporter and LMP genes implied that there
was an additional factor(s) involved in the assembly and transport of
the class I complex. The following possibilities were considered:
(a) differences in the steady state level of H-2Kb and H-2Db mRNA, leading to
differences in the magnitude of their expression; (b)
differences in the translation efficiency of class I transcripts, resulting in differences in the amounts of proteins produced; (c) mutations affecting the conformation of the endogenous
class I molecules and, thus preventing their transport through cell organelles; and (d) competition among class I heavy chains
for limited amounts of 2m or inaccessible
2m molecules, leading to selective enrichment in
particular class I complexes.
Our data show that equal amounts of H-2Kb and
H-2Db genes were transcribed (Fig. 2). We also found that
PD1 and H-2 mRNAs were translated efficiently (Fig. 3). In one
Ad12-transformed cell line (VAD12.79), we observed some inhibition in
the translation of 2m mRNA as compared with that in
the normal cell line M1. However, even in this cell line,
2m mRNA was associated with the polysomal fraction
and the slight shift of its mRNA toward association with lighter
polysomes was not detected in other Ad12-transformed cell lines. Thus,
aberrant transcription or translation of the class I heavy chains or of
2m molecules cannot account for the low level of
assembled and transported H-2 molecules in the TAP and
LMP-reconstituted Ad12-transformed cells.
In order to determine whether inefficient assembly of specific class I
heavy chains resulted from mutations in the endogenous genes which
affect their conformation, we previously overexpressed either H-2 or
2m molecules via infection with recombinant vaccinia viruses and analyzed their assembly and transport (34). The results
were comparable with those obtained with the endogenous molecules,
i.e. the transport of H-2 molecules was inefficient, while
the transport of PD1 was completely restored. In the present study we
also found that TAP-reconstituted VAD12.79 cells stably transfected
with a 2m gene show enhanced assembly and transport of
PD1, but not of H-2 molecules (Fig. 4).
Collectively, the data suggested that one of the components
( 2m or peptides) of the class I complex was not
available for assembly and led us to compare in greater detail the fate
of 2m in the normal versus the transformed
cells. Based on our previous immunoprecipitation data and on other
studies (45, 46, 47, 48, 49), it seemed likely that in normal cells most of the 2m molecules would be associated with class I heavy
chains and free molecules would either be degraded or secreted. Several
studies have shown that free 2m is secreted from cells
and that its secretion can be enhanced by various cytokines, growth
factors, and growth promoters (47, 48, 49). Dragmont et al. (45)
demonstrated that free 2m was secreted into the culture
media of cell lines independent of cell surface expression of class I
heavy chains. 2m has also been shown to be secreted from
endometrial cells (46), leukemic B cells (47), fibroblasts (48), and
hepatocytes (49). Much less is known about the degradation pathway of
free 2m within the cells. Since in Ad12-transformed
cells there is no assembly with class I heavy chains, it seemed likely
that most of the 2m would be secreted from the cells or
rapidly degraded. However, surprisingly, unlike normal and
E1Ad5-transformed cells in which free 2m was either
secreted or degraded, and class I-assembled 2m was
transported to the cell membrane, in Ad12-transformed cells, free
2m was retained in the cells (Fig. 5). Furthermore, we
found that most of the 2m molecules in the transformed
cells resided in the membrane-enriched fraction (Fig. 7) and were more efficiently retained, following an overnight labeling period, than in
the normal cell line. These data suggest that in the absence of
detectable assembly with class I heavy chains, 2m
molecules could bind other membrane-associated molecules, resulting in
the retention of these molecules within the cell. We cannot completely rule out the possibility of the existence of denatured class I heavy
chains in Ad12-transformed cells that have lost all epitopes recognized
by the antibodies used for immunoprecipitations and still have the
potential to bind 2m efficiently and to be retained in a
stable form in the ER. Nevertheless, this possibility seems highly
unlikely in view of the fact that none of the panel of antibodies
directed against epitopes on the 3 domain of
H-2Db (33), H-2Dd (34), PD1 (33, 34), and
antisera against peptide 8 of the H-2Kb molecules (data not
shown) detected significant assembly of the relevant heavy chain with
2m.
Since it has been documented that -interferon modulates the
secretion of 2m (47, 49) and the same cytokine also
reconstitutes the transport of H-2 molecules in Ad12-transformed cells
(Ref. 34, and data not shown), we pretreated the transformed cells with
interferons and determined the half-life of 2m. Indeed, interferon treatment significantly shortened the half-life of 2m, but it was still longer than in normal or
E1Ad5-transformed cells. Thus, we can conclude that in Ad12-transformed
cells, most 2m is retained in the cells via a
membrane-bound component and that it can be partially released by
assembly with a class I heavy chain/peptide or by interferon
treatment.
2m is known to bind at least two other non-MHC molecules
that have low significant homology with class I heavy chains: the neonatal Fc receptor (50, 51) and the CD1 class I-like molecule (51,
52). Neonatal Fc receptors mediate transfer of maternal IgG to the
newborn, providing the neonate with humoral immunity before the
development of a fully functional immune system. The neonatal Fc
receptor shows similarity to the class I heavy chains in the
organization of domains and their sequence, especially in the
3 domain (53), a fact that explains its binding to
2m molecules. On the other hand, the non-MHC-encoded CD1
family of molecules present antigens entirely distinct from MHC class
I, class II, or related molecules (51). The molecules are abundantly expressed on professional antigen-presenting cells and are associated with 2m, and their expression and function is
independent of the expression of peptide-transporter molecules (52).
Thus, it is clear that 2m can bind class I-related
proteins with apparently diverse functions. It is tempting to speculate
that 2m can function as a scaffold for multiple proteins
and promote their correct folding, as suggested by Solheim et
al. (54) for class I heavy chains. In the latter case
2m would participate in class I transport not only by
stabilization of the class I heavy chains, but also by induction of a
heavy chain conformation that enables it to transit to the cell
surface. The same group also demonstrated (55) that 2m
was associated with TAP in a class I negative cell line, supporting the
hypothesis that 2m can bind to multiple proteins within
the cell, either directly or via another molecule(s).
Since 2m could function to stabilize and maintain a
variety of proteins, the constitutive secretion of 2m by
a variety of cells may have an important physiological role. Indeed,
free 2m has been shown to have some unexpected
biological activities. 2m produced by synovial
fibroblasts stimulated by phorbol esters induced collagenase synthesis
in these cells (56). 2m also increased the number of
insulin-like growth factor I transcripts and polypeptides, as well as
their receptors, on cultured bone marrow cells (57). These data
suggested that 2m could be involved in the modulation of
connective tissue breakdown and bone remodeling. 2m
might also play a role in the migration of hematopoietic cell precursors from their site of emergence, the bone marrow, to their site
of differentiation, the thymus, since it is produced by a thymic
epithelial cell line and is able to induce oriented migration of
immature lymphoid bone marrow cells in vitro (58). Cytokines and growth factors that were reported to enhance 2m
secretion possibly could act via two mechanisms: enhancement of
2m transcription and induction of 2m
release from specific cellular proteins that might be similar to the
2m-binding proteins described in this paper.
Another system that is similar in several aspects to that described
above is the association of surrogate immunoglobulin light chains with
glycoproteins in cells that do not express the immunoglobulin heavy
chain (59). The complex of µ heavy chain/surrogate light chain is
expressed on pre-B cell lines and has been found to transmit biochemical signals to the cells (60, 61). However, the surrogate light
chain can be expressed on the cell surface in the absence of rearranged
heavy chain. Several proteins were suggested as potential candidates
for binding non-covalently the surrogate light chain and carrying it to
the surface of pre-B and pro-B cell lines (59). Unlike the surrogate
light chains, some classical immunoglobulin light chains, in the
absence of heavy chains, are retained and degraded within the ER (62).
The half-life of these molecules depends on their binding and
dissociation from the chaperone BiP. Our data suggest that, like the
surrogate light chains, 2m molecules can bind other
molecules in the absence of efficient assembly with class I heavy
chains. However, such molecules either have long half-life (>5 h)
and/or they are not transported to the cell surface and remain
associated with 2m molecules in the cells. Whether these
2m-binding molecules are expressed in normal cells, or
are known chaperons such as BiP or calnexin that bind misfolded
proteins, or are novel proteins, which are overexpressed in
Ad12-transformed cells, remains to be determined. The fact that in
Ad12-transformed cells the membrane fraction is enriched with
2m suggests that at least one binding protein is a
membrane-bound protein such as calnexin. However, calnexin is commonly
thought to be a chaperone that binds mostly glycoproteins (63),
although a different mechanism for its association with class I heavy
chains and class II invariant chains has been suggested (64, 65). Both
of these molecules associated with calnexin even when their glycosylation was inhibited, and in the latter case, calnexin association retained the invariant chain in the ER and prevented its
degradation. Thus, it is conceivable that 2m binds
calnexin or another molecule via a mechanism similar to that involved
in class II invariant chain association.
If Ad12-transformed cells overexpress a 2m-binding
protein, it might interfere with the assembly of class I heavy
chain/ 2m/peptide. The ability of this protein to
successfully compete with class I heavy chains for 2m
binding could explain our inability to fully restore the assembly of
the H-2 complex in TAP+LMP-reconstituted cells. Thus, Ad12-transformed
cells appear to acquire a novel membrane-associated mechanism for
sequestering 2m. This mechanism may be unique to these
cells or may be induced in cells that do not express fully conformed
class I complexes.
FOOTNOTES
*
This work was supported by the US-Israel Binational Science
Fund, by a grant from the Israel Health Ministry, and by the Israel Association Against Cancer Foundation. The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 972-3-6409238;
Fax: 972-3-6422046; E-mail: rachele{at}ccsg.tau.ac.il.
1
The abbreviations used are: MHC, major
histocompatibility complex; TAP, transporter associated with antigen
presentation; ER, endoplasmic reticulum; PBS, phosphate-buffered
saline; Endo H, endoglycosidase H; PCR, polymerase chain reaction;
RT-PCR, reverse transcription-PCR; PSL, phosphostimulated luminescence; LMP, low molecular mass protein.
Acknowledgment
We are grateful to Dr. John E. Coligan (NIAID,
National Institutes of Health) for the critical reviewing of the
manuscript.
REFERENCES
-
Zinkernagel, R., and Doherty, P. C.
(1979)
Adv. Immunol.
22,
51-177
-
Goodenow, R. S., Vogel, J. M., and Linsk, R. L.
(1985)
Science
230,
777-783
[Abstract/Free Full Text]
-
Hämmerling, G. J., Klar, D., Pulm, W., Momburg, F., and Moldenhauer, G.
(1987)
Biochim. Biophys. Acta
179,
245-259
-
Ehrlich, R.
(1995)
Immunol. Res.
14,
77-97
[Medline]
[Order article via Infotrieve]
-
Yewdell, J. W., and Bennink, J. R.
(1992)
Adv. Immunol.
52,
1-123
[Medline]
[Order article via Infotrieve]
-
Germain, R. N., and Margulies, D. H.
(1993)
Annu. Rev. Immunol.
11,
403-450
[CrossRef][Medline]
[Order article via Infotrieve]
-
Spies, T., and DeMars, R.
(1991)
Nature
351,
323-324
[CrossRef][Medline]
[Order article via Infotrieve]
-
Attaya, M., Jameson, S., Martinez, C. K., Hermel, E., Aldrich, C., Forman, J., Fischer Lindahl, K., Bevan, M. J., and Monaco, J. J.
(1992)
Nature
355,
647-649
[CrossRef][Medline]
[Order article via Infotrieve]
-
Van Kaer, L., Ashton-Rickardt, P. G., Ploegh, H. L., and Tonegawa, S.
(1992)
Cell
71,
1205-1214
[CrossRef][Medline]
[Order article via Infotrieve]
-
Arnold, D., Driscoll, J., Androlewicz, M., Hughes, E., Creswell, P., and Spies, T.
(1992)
Nature
360,
171-174
[CrossRef][Medline]
[Order article via Infotrieve]
-
Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mule, J. J., Rosenberg, S. A., and Bennink, J.
(1993)
J. Exp. Med.
177,
265-272
[Abstract/Free Full Text]
-
Rotem-Yehudar, R., Winograd, S., Sela, S., Coligan, J. E., and Ehrlich, R.
(1994)
J. Exp. Med.
180,
477-488
[Abstract/Free Full Text]
-
Williams, D. B., Barber, B. H., Flavell, R. A., and Allen, H.
(1989)
J. Immunol.
142,
2796-2806
[Abstract]
-
Zijlstra, M., Bix, M., Simister, N. E., Loring, J. M., Raulet, D. H., and Jaenisch, R.
(1990)
Nature
344,
742-746
[CrossRef][Medline]
[Order article via Infotrieve]
-
Koller, B. H., Marrack, P., Kappler, J. W., and Smithies, O.
(1990)
Science
248,
1227-1230
[Abstract/Free Full Text]
-
Rock, K. L., Rothstein, L. E., Gamble, S. R., and Benacerraf, B.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
7517-7521
[Abstract/Free Full Text]
-
Vitiello, A., Potter, T. A., and Sherman, L. A.
(1990)
Science
250,
1423-1426
[Abstract/Free Full Text]
-
Rock, K. L., Gamble, S., Rothstein, L., and Benacerraf, B
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
301-304
[Abstract/Free Full Text]
-
Kozlowski, S., Takeshita, T., Boehncke, W.-H., Takahashi, H., Boyd, L. F., Germain, R. N., Berzofsky, J. A., and Margulies, D. H.
(1991)
Nature
349,
74-77
[CrossRef][Medline]
[Order article via Infotrieve]
-
Boyde, L. F., Kozlowski, S., and Margulies, D. H.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
2242-2250
[Abstract/Free Full Text]
-
Otten, G. R., Bikoff, E., Ribaudo, R. K., Kozlowski, S., Margulies, D. H., and Germain, R.
(1992)
J. Immunol.
148,
3723-3732
[Abstract]
-
Abdel Motal, U., Zhou, M., X., Siddiqi, A. R., and Jondal, M.
(1993)
Scand. J. Immunol.
38,
395-400
[CrossRef][Medline]
[Order article via Infotrieve]
-
Rock, k. L., Gamble, S., Rothstein, L., Gramm, C., and Benacerraf, B.
(1991)
Cell
65,
611-620
[CrossRef][Medline]
[Order article via Infotrieve]
-
Manicourt, D., Brauman, H., and Orloff, S.
(1978)
Ann. Rheum. Dis.
37,
328-332
[Abstract/Free Full Text]
-
Maury, C. P. J., Helve, T., and Sjoblom, C.
(1982)
Rheumatol. Int.
2,
145-149
[CrossRef][Medline]
[Order article via Infotrieve]
-
Child, J. A., Spati, B., and Illingworth, S.
(1980)
Cancer
45,
318-326
[CrossRef][Medline]
[Order article via Infotrieve]
-
Goldman, M. H., Landwehr, D. M., and Lippman, R.
(1982)
Transplant. Proc.
14,
437-439
[Medline]
[Order article via Infotrieve]
-
Beorcia, S., Vincent, C., and Revillard, J. P.
(1981)
Clin. Chim. Acta
109,
245-255
[CrossRef][Medline]
[Order article via Infotrieve]
-
Hoffmann, B., Baas, H., Nishanian, P., Faisal, M., Figlin, R. A., Sarna, G. P., and Fahey, J. L.
(1992)
Clin. Exp. Immunol.
88,
548-554
[Medline]
[Order article via Infotrieve]
-
Homma, T., Tsujinaka, T., Kido, Y., Yasuda, T., Murata, A., and Mori, T.
(1992)
Eur. Surg. Res.
24,
204-210
[Medline]
[Order article via Infotrieve]
-
Rock, K. L., Fleischacker, C., and Gamble, S.
(1993)
J. Immunol.
150,
1244-1252
[Abstract]
-
Shemesh, J., Rotem-Yehudar, R., and Ehrlich, R.
(1991)
J. Virol.
65,
5544-5548
[Abstract/Free Full Text]
-
Shemesh, J., and Ehrlich, R.
(1993)
J. Biol. Chem.
268,
15704-15711
[Abstract/Free Full Text]
-
Rotem-Yehudar, R., Groettrup, M., Soza, A., Kloetzel, P.-M., and Ehrlich, R.
(1996)
J. Exp. Med.
183,
499-514
[Abstract/Free Full Text]
-
Jacoby, W. B., and Pastan, I. H.
(1979)
Methods Enzymol.
58,
110-116
[Medline]
[Order article via Infotrieve]
-
Ozato, K., and Sachs, D. H.
(1981)
J. Immunol.
126,
317-321
[Abstract]
-
Davis, W. C., Marusic, S., Lewin, H. A., Splitter, G. A., Perryman, L. E., McGuire, T. C., and Gorham, J. R.
(1987)
Vet. Immunol. Immunopathol.
15,
337-376
[CrossRef][Medline]
[Order article via Infotrieve]
-
Current Protocols in Immunology, pp. 81.2-8.1.5, John Wiley & Sons, New YorkColigan, J. E., Kruisbeek, A. M., Margulies, D., Shevach, E. M., and
Strober, W. (eds). (1994) Current Protocols in Immunology,
pp. 81.2-8.1.5, John Wiley & Sons, New York
-
Cleveland, D. W., Lopata, M. A., MacDonald, R. J., Cowan, N. J., Rutter, W. J., and Kirschner, M. W.
(1980)
Cell
20,
95-105
[CrossRef][Medline]
[Order article via Infotrieve]
-
Levitsky, H. I., Lazenby, A., Hayashi, R. J., and Pardoll, D. M.
(1994)
J. Exp. Med.
179,
1215-1224
[Abstract/Free Full Text]
-
White, B. A., and Bancroft, F. C.
(1982)
J. Biol. Chem.
257,
8569-8572
[Abstract/Free Full Text]
-
Meyuhas, O., Thompson, E. A., Jr., and Perry, R.
(1987)
Mol. Cell. Biol.
7,
2691-2699
[Abstract/Free Full Text]
-
Moonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andruilis, I. L., Gazdar, A. F., Willman, C. L., Griffin, B., Von Hoff, D. D., and Robinson, I. B.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
7160-7164
[Abstract/Free Full Text]
-
Chelly, J., Kaplan, J.-C., Maire, P., Gautron, S., and Kahn, A.
(1988)
Nature
333,
858-860
[CrossRef][Medline]
[Order article via Infotrieve]
-
Dargemont, C., Dunon, D., Salamero, J., Deugnier, M. A., Davoust, J., and Thierry, J. P.
(1991)
J. Cell. Sci.
98,
559-565
[Abstract/Free Full Text]
-
Vallet, J. L., Barker, P. J, Lamming, G. E., Skinner, N., and Huskisson, N. S.
(1991)
J. Endocrinol.
130,
R1-4
[Abstract/Free Full Text]
-
Jones, R. A., Drexler, H. G., Gignac, S. M., Child, J. A., and Scott, C. S.
(1990)
Br. J. Cancer
61,
675-680
[Medline]
[Order article via Infotrieve]
-
Golds, E. E., Mason, P., and Nyirkos, P.
(1989)
Biochem. J.
15,
585-588
-
Ramadory, G., Mitch, A., Rieder, H., and Meyer-zum-Buschenfelde, K. H.
(1988)
Eur. J. Clinic. Invest
18,
343-351
[Medline]
[Order article via Infotrieve]
-
Israel, E. J., Patel, V. K., Taylor, S. F., Marshak-Rothstein, A., and Simister, N. E.
(1995)
J. Immunol.
154,
6246-6251
[Abstract]
-
Beckman, E. M., and Brenner, M. B.
(1995)
Immunology Today
16,
349-352
[CrossRef][Medline]
[Order article via Infotrieve]
-
Brutkicwicz, R. R., Bennink, J. R., Yewdell, J. W., and Bendelac, A.
(1995)
J. Exp. Med.
182,
1913-1919
[Abstract/Free Full Text]
-
Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L., and Bjorkman, P. J.
(1994)
Nature
372,
336-343
[CrossRef][Medline]
[Order article via Infotrieve]
-
Solheim, J. C., Johnson, N. A., Carreno, B. M., Lie, W. R., and Hansen, T. H.
(1995)
Eur. J. Immunol.
25,
3011-3016
[Medline]
[Order article via Infotrieve]
-
Carreno, B. M., Solheim, J. C., Harris, M., Stronowski, I., Connoly, J. M., and Hansen, T. H.
(1995)
J. Immunol.
155,
4726-4733
[Abstract]
-
Brinckerhoff, C. E., Mitchell, T. I., Karmilowicz, M. J., Kluve-Beckerman, B., and Benson, M. D.
(1989)
Science
243,
655-657
[Abstract/Free Full Text]
-
Centrella, M., McCarthy, T. L., and Canalis, E.
(1989)
J. Biol. Chem.
264,
18268-18271
[Abstract/Free Full Text]
-
Dargemont, C., Dunon, D., Deugnier, M.-A., Denoyelle, M., Girault, J.-M., Lederer, F., Le, K. H. D., Godeau, F., Thierry, J. P., and Imhof, B. A.
(1989)
Science
246,
803-806
[Abstract/Free Full Text]
-
Karasuyama, H., Rolink, A., and Melchers, F.
(1993)
J. Exp. Med.
178,
469-478
[Abstract/Free Full Text]
-
Misner, V., Downey, G. P., and Jongstra, J.
(1991)
Int. Immunol.
3,
1129-1136
[Abstract/Free Full Text]
-
Takemori, T., Mizuguchi, J., Miazoe, I., Nakanishi, M., Shigemoto, K., kimoto, H., Shirasawa, T., Naruyama, N., and Taniguchi, M.
(1990)
EMBO J.
9,
2493-2500
[Medline]
[Order article via Infotrieve]
-
Knittler, M. R., Dirks, S., and Haas, I. G.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
1764-1768
[Abstract/Free Full Text]
-
Hammond, C., Braakman, I., and Helenius, A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
913-917
[Abstract/Free Full Text]
-
Carreno, B. M., Schreiber, K. L., McKean, D. J., Stronowski, I., and Hansen, T. H.
(1995)
J. Immunol.
54,
5173-5180
-
Romagnoli, P., and Germain, R. N.
(1995)
J. Exp. Med.
182,
2027-2036
[Abstract/Free Full Text]
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Mori, Y. Terui, M. Ikeda, H. Tomizuka, M. Uwai, T. Kasahara, N. Kubota, T. Itoh, Y. Mishima, M. Douzono-Tanaka, et al.
beta 2-Microglobulin Identified as an Apoptosis-Inducing Factor and Its Characterization
Blood,
October 15, 1999;
94(8):
2744 - 2753.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. V. Fromm, S. W. Mey-Tal, J. E. Coligan, C. Schechter, and R. Ehrlich
MHC Class I Heavy Chain mRNA Must Exceed a Threshold Level for the Reconstitution of Cell Surface Expression of Class I MHC Complexes in Cells Transformed by the Highly Oncogenic Adenovirus 12
J. Biol. Chem.,
June 12, 1998;
273(24):
15209 - 15216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Chatterjee-Kishore, F. van den Akker, and G. R. Stark
Adenovirus E1A Down-regulates LMP2 Transcription by Interfering with the Binding of Stat1 to IRF1
J. Biol. Chem.,
June 30, 2000;
275(27):
20406 - 20411.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|